MLchartDataset catalogue

RIVAC regimen

Term · Oncology and biomedicine · MLC-T-ONC-016559

A regimen consisting of rituximab, ifosfamide, cytarabine and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL).

Table 1. Record
IdentifierMLC-T-ONC-016559
FieldOncology and biomedicine
AbbreviationRIVAC
Synonymsrituximab/ifosfamide/cytarabine/etoposide; rituximab-ifosfamide-cytarabine-etoposide; rituximab + ifosfamide + cytarabine + etoposide; R-IVAC regimen; rituximab/ifosphamide/VP-16/ARA-C
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON 
{
  "id": "MLC-T-ONC-016559",
  "term": "RIVAC regimen",
  "field": "Oncology and biomedicine",
  "definition": "A regimen consisting of rituximab, ifosfamide, cytarabine and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL).",
  "abbreviation": "RIVAC",
  "synonyms": [
    "rituximab/ifosfamide/cytarabine/etoposide",
    "rituximab-ifosfamide-cytarabine-etoposide",
    "rituximab + ifosfamide + cytarabine + etoposide",
    "R-IVAC regimen",
    "rituximab/ifosphamide/VP-16/ARA-C"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/rivac-regimen/"
}

Record 14,519 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.